Genoscience Pharma

Genoscience Pharma is a private, clinical-stage biotech innovating in oncology and fibrotic diseases by targeting lysosomal biology. Its lead asset, GNS561, is in clinical development for primary liver cancers, and the company has secured European funding for a program in idiopathic pulmonary fibrosis (IPF). The company leverages a novel scientific platform and has established key partnerships, such as an exclusive licensing deal with Genfit for GNS561 in oncology, to advance its pipeline.

Lysosome-targeting small molecules and PROTAC technology to disrupt cancer cell metabolism and protein homeostasis.

In oncology, Genoscience competes with numerous pharma companies developing targeted therapies and immunotherapies for liver cancer. In IPF, it would compete against approved anti-fibrotics (pirfenidone, nintedanib) and a pipeline of novel agents. Its differentiation lies in its first-in-class lysosomal and PROTAC-based mechanisms.